Prof Simon Harrison
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
479 Scholarly works
14 Projects
HIGHLIGHTS
2026
Journal article
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial
DOI: 10.1186/s41687-026-01034-z2026
Journal article
A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases
DOI: 10.1038/s41698-026-01462-62026
Journal article
Early-Life Exposures and Risk of Multiple Myeloma: A Population-Based Case–Control Study in Australia
DOI: 10.1002/ijc.705392026
Research grants (international)
Using Novel Biological Therapies to Target a Tumor-Specific Isoform of HER2 for the Treatment of Advanced Breast Cancer.
2021
Research grants (ARC, NHMRC, MRFF)
Studying the Origins, Maintenance and Resistance Mechanisms of Poor Risk Paediatric Leukaemia at Single Cell Resolution to Develop Novel Therapeutic Approaches
2020
Research Grant
ProTreat: An Adaptive and Rapid Implementation Trial of Novel Therapies to Prevent and Treat COVID19 Infection in High Risk Cancer Patients
2017
Journal article
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
DOI: 10.1182/blood-2017-06-788323
RECENT SCHOLARLY WORKS
2026
Journal article
Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.
DOI: 10.1182/bloodadvances.20260204982026
Journal article
Author reply.
DOI: 10.1111/imj.706412026
Journal article
T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.
DOI: 10.1182/bloodadvances.20260205032026
Journal article
Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.
DOI: 10.1182/bloodadvances.20260216182026
Journal article
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis
DOI: 10.1002/ajh.703762026
Journal article
MM-1092: Trial in Progress: QUINTESSENTIAL-2, a Phase 3 Study of Arlocabtagene Autoleucel vs Standard of Care in Adult Patients With Relapsed/Refractory Multiple Myeloma Exposed to Lenalidomide
DOI: 10.1016/s2152-2650(26)02983-62026
Journal article
POSTER: MM-1092: Trial in Progress: QUINTESSENTIAL-2, a Phase 3 Study of Arlocabtagene Autoleucel vs Standard of Care in Adult Patients With Relapsed/Refractory Multiple Myeloma Exposed to Lenalidomide
DOI: 10.1016/s2152-2650(26)01409-6
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Next Generation Cellular Immunotherapy for Multiple Myeloma and Beyond